SAN DIEGO – Buzzing through the halls, amid private discussions and public panels, a technology that some say could dramatically transform therapeutic development teeters at the forefront of many BIO 2017 discussions.
About a year after legislators lambasted Turing Pharmaceuticals’ former CEO, Martin Shkreli, for hiking by 5,000 percent the price of life-saving toxoplasmosis drug Daraprim, a firestorm has pummeled the biopharmaceutical industry, publicly shaming at least eight companies for drug price increases and demanding laws for transparency, negotiation, bidding and reimportation.
A handful of generic company takeovers and several buyouts by Dublin-based biopharmas highlighted the mergers and acquisitions landscape in 2016, in which BioWorld recorded 144 deals representing a $143 billion value.
The biopharmaceutical industry won a nearly $80 billion vote of confidence in 2016 by way of 814 deals tracked by BioWorld, with most occurring in the months of January and December.
Biopharmaceutical financings have taken a strong stance in 2016, coming in third for the most money raised in a single year since BioWorld began tracking financings 20 years ago.
Manufacturing issues. New trials. Miscommunications. Unclear expectations. So go company conversations following the often unexpected receipt of the much-dreaded complete response letter (CRL).
With only a few weeks remaining in 2016, the biopharmaceutical industry has welcomed 131 FDA approvals this year, including 19 for new molecular entities.
As interest builds in the field of bispecific antibodies, one-year-old China-based Epimab Biotherapeutics Inc. is preparing for a series A financing and just announced its first licensing deal for the company's flagship technology platform, FIT-Ig – or Fabs-In-Tandem.
CHICAGO – Immunotherapy is increasingly becoming a pillar of cancer treatment, as checkpoint inhibitors continue to demonstrate tumor regression and survival benefits, and a growing body of biomarker research informs treatment decisions.
